Biocon Biologics Recognized as a Company with Great Managers; Two Managers conferred with individual ‘Great Managers Award 2022’

  • Posted by: Biocon Biologics

Bengaluru, Karnataka, India, December 22, 2022

Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), announced  today that it has been recognized as a Company with Great Managers at the Great Manager Awards (GMA) 2022. Biocon Biologics is among the Top 50 Companies among 175 participating companies to feature on this prestigious  list.

In the individual category, Jesu Prabhalan from BBL’s Projects Division and Vikas Jawalkar from the Company’s Regulatory Affairs function won the ‘Great Managers Award’ for 2022. They were among the 51 managers nominated by BBL for the ‘Top 100 Great Managers’ recognition. This year, over 6,000 managers were nominated by over 175 organizations. Of these, 300 were shortlisted for the interview round and selection to the Top 100 list.

Speaking on this recognition, Shreehas Tambe, Chief Executive Officer & Managing Director, Biocon Biologics, said: I am pleased to see Biocon Biologics being recognized as a ‘Company with Great Managers’. This success is thanks to our focused talent development programs, and a work culture that nurtures talent and empowers people. I would also like to congratulate Jesu Prabhalan and Vikas Jawalkar for winning the ‘Great Managers Award 2022’ in the individual category. I extend my appreciation to both and wish them success in their leadership journey”

The Great Manager Awards Program, an initiative by global human resource management consulting firm People Business, identifies, recognizes, and rewards organizations with ‘Great Managers’ in India. This program enables the participant organizations to compare and benchmark themselves and their managers across the industry by making their organizations great places to work for great managers.

The winners were selected from the managers nominated by the companies participating in the Great Manager Awards survey, based on an interview with the jury compromising CEOs, leaders from the Industry, Academia and People Business. The study was supported by over 60 CEOs and over 40 CHROs and 20 Professors as members of the advisory panel.

People Business is a global human resources management consulting firm, which provides performance and talent management solutions through efficient, customized, implementable consulting services.

About Biocon Biologics Limited:

Biocon Biologics Ltd. (BBL), a subsidiary of Biocon Ltd., is a unique, fully integrated, global biosimilars company committed to transforming healthcare and transforming lives by enabling affordable access to affordable biologics for millions of patients worldwide. It is leveraging cutting-edge science, innovative tech platforms, global scale manufacturing capabilities and world class quality systems to lower costs of biological therapeutics while improving healthcare outcomes. BBL has acquired the global biosimilars business of its long-standing partner Viatris, which is a historic milestone in its value creation journey. Biocon Biologics has commercialized eight biosimilars in key emerging markets and advanced markets like U.S., EU, Australia, Canada, Japan.

The Company has a pipeline of 20 biosimilar assets across diabetology, oncology, immunology, and other non-communicable diseases. It has many ‘firsts’ to its credit in the biosimilars industry. It has also signed a strategic alliance with Serum Institute Life Sciences for vaccines (subject to certain closing conditions) to address the inequitable access to lifesaving vaccines. As part of its environmental, social and governance (ESG) commitment, BBL is advancing the health of patients, people and the planet to achieve key UN Sustainable Development Goals (SDGs). Website:; Follow us on Twitter: @BioconBiologics for company updates.

Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US and Europe. It also has a pipeline of promising novel assets in immunotherapy under development. Website:; Follow-us on Twitter: @bioconlimited for company updates.

Author: Biocon Biologics
buy twitter followers